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ficient inhibitor of HIV-1 reverse transcriptase than of cellular polymerase a [12] . Replication of HIV-1 in human peripheral mononuclear cells and in the H-9 T cell line was inhibited by AZT at concentrations of 1-10 nM [9] .
In vivo studies have shown that AZT has good oral bioavailability and is efficiently transported across the blood-brain barrier [13] . The drug is rapidly absorbed after oral administration and has a half-life of M h. In 1985, a phase 1 trial was undertaken with 19 patients with AIDS or AIDS-related complex; in several patients the clinical and immunological status improved [13] . A phase 2 randomized trial with 282 patients followed; however, this study was ended prematurely when opportunistic infections and deaths declined in the AZT-treated group [14] .
Several studies have reported that HIV-1 can successfully infect B cells [15] [16] [17] . One study reported that B cells were transformed by Epstein-Barr virus (EBV), at times before infection by HIV-1, thus resulting in enhanced HIV-1 replication [17] . We investigated the ability of AZT to prevent infection and replication of HIV-1 in EBV-transformed B cells because infected B cells may serve as a reservoir of HIV-1 within infected individuals and because AZT has become the most widely used drug in treating HIV-1 infections. We used two clinical isolates of HIV-1 in our study and the human T cell leukemia virus-IIlB (HTLV-IHb) laboratory strain.
Materials and Methods
Cell lines. Density gradient centrifugation (Ficoll-Paque, Pharmacia, Piscataway, NJ) was used to separate peripheral blood mononuclear cells from umbilical cord blood [18] . To obtain lines of EBVtransformed B cells, suspensions of 106 umbilical cord mononuclear cells/ml (0.8 ml) were coincubated with 0.2 ml of a suspension of infectious EBV at 370C [19] . (Cell-free supernatants of the B95-8 marmoset cell line, cultured for 7 d without change of medium, were used as a source of infectious EBV.) Thereafter, establishment of lymphoblastoid cell lines was determined by formation of clumps of cells and ability to sustain frequent subdivisions [20] . Fresh RPMI 1640 medium (GIBCO, Mississauga, Ont), supplemented with L-glutamine (2 mM), streptomycin (250 ng/ml), penicillin (250 units/ml), and ^o (vol/vol) fetal bovine serum was added twice weekly.
After * AZT was present before, during, and after the viral adsorption period. Finally, we evaluated the uptake of AZT by our EBV-transformed B cell lines and by H-9 cells. Cells were exposed, as described in Materials and
Methods, to a preparation of [3H] AZT. The uptake of [3H] AZT was virtually identical in the uninfected H-9 lymphocytes (15.35 pmol), in an uninfected EBVtransformed B cell line (11.75 pmol), and in an HIV-1 (HTLV-IIIb strain)-infected EBV-transformed B cell line (16.3 pmol).
We also tested the effect of AZT on EBVtransformed B cells that were preinfected by HIV-1. were then continuously treated with each of the three concentrations of AZT used in our study (1, 5, and 10 \iM). Table 3 Our study is thought to be the first to show differential sensitivity of HIV-1 variants in susceptibility to AZT. We deliberately extended our study over long periods to ascertain whether such differential sensitivity might exist.
NOTE. Culture Huids from HIV-1-infected EBV-transformed B cells were harvested and used to infect MT-4 cells as described in Materials and
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